ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKER01

Novel Therapeutic Approaches for NPC Disease

Active
Institution
UNIVERSITY OF ILLINOIS AT CHICAGO, IL
Principal investigator
Stephanie M Cologna
Funding
$576K
Duration
2022–2027
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY/ABSTRACT Niemann-Pick disease, type C1 (NPC1), is an autosomal recessive, neurovisceral disorder, and patients typically succumb to complications of the disease in the early adulthood years. The clinical phenotype of NPC1 is broad including both central nervous system and peripheral dysfunction and currently there is no FDA- approved therapy. The enclosed proposal seeks to develop and understand the mechanism of action of a new class of peptides to ameliorate cholesterol storage and associated phenotypes of NPC1. Our central approach is to address the biochemical deficits upstream of the NPC1 protein. First, we will understand how defined protein and lipid biomarkers respond to peptide treatment. Second, we will perform a DMPK study and investigate lifespan extension with treatment. Third, we will investigate the mechanism of action by which these peptides reduce cholesterol storage. To carry out the proposed project, we will leverage our expertise in mass spectrometry, biochemistry and molecular biology techniques.

Research team

  • Vinay AakaluPI
  • Stephanie M ColognaPI

LOADING MOONBASE SCORE

R01NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEDrug Discovery for the Nervous System Study Section[DDNS]cholesterolstoragepeptidesmechanism actionautosomal recessivebiochemistry molecularnpcbiology techniques

Questions for UNIVERSITY OF ILLINOIS AT CHICAGO

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.